Feeding Trial in the Obese Critical Care Population
Enteral Formula Tolerance in the Obese Critical Care Population
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 years
- Surgical or Medical intensive care unit (ICU) patient
- Body mass index (BMI) ≥ 30
Exclusion Criteria:
- pregnant or lactating
- unable to access gastrointestinal (GI) tract for feeding via tube
- other contraindication to tube feeding
- admitted with burns
- severe head trauma
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
critically ill obese adults
Age ≥ 18 years, body mass index (BMI) ≥ 30, in intensive care unit (ICU) requiring tube feeding ≥ 3 days
|
Complete feeding of study enteral formula, route and regime prescribed by the physician.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
time to feeding goal achievement
Time Frame: up to 5 days
|
on all participants
|
up to 5 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
gastrointestinal measures assessment
Time Frame: daily for up to 11 days
|
on all participants
|
daily for up to 11 days
|
|
percent of nutrition goal met
Time Frame: up to 5 days
|
on all participants
|
up to 5 days
|
|
serum biochemical markers assessment
Time Frame: daily for up to 11 days
|
on all participants
|
daily for up to 11 days
|
|
assessment of frequency and nature of adverse events
Time Frame: daily for up to 11 days
|
on all participants
|
daily for up to 11 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 10.02.US.CLI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.